[ad_1] – Study failed to meet primary and secondary efficacy endpoints – WARREN, N.J., Nov. 26, 2024 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the global Phase 2 placebo-controlled CardinALS study did […]
Tag: PTC Therapeutics
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
[ad_1] WARREN, N.J., Oct. 25, 2024 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Oct. 23, 2024, the company approved non-statutory stock options to purchase an aggregate of 13,690 shares of its […]
PTC Therapeutics Announces FDA Target Regulatory Action Date for Sepiapterin and Lancet Publication of Phase 3 Trial Results
[ad_1] WARREN, N.J., Oct. 14, 2024 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the FDA has set a target regulatory action date of July 29, 2025, for the review of the New Drug Application (NDA) […]
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
[ad_1] WARREN, N.J., Sept. 12, 2024 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Sept. 8, 2024, the company approved non-statutory stock options to purchase an aggregate of 16,180 shares of its common […]
